Silvana Zanlungo

Title: Silvana Zanlungo: Innovator in c-Abl Tyrosine Kinase Inhibitors

Introduction

Silvana Zanlungo is a prominent inventor based in Santiago, Chile. She has made significant contributions to the field of biomedical research, particularly in the development of compounds that inhibit c-Abl tyrosine kinase. With a total of 2 patents, her work focuses on therapeutic agents that can address critical health issues.

Latest Patents

Zanlungo's latest patents include innovative embodiments of a compound that inhibits c-Abl tyrosine kinase. These compounds are designed to bind to c-Abl at an allosteric site, effectively inhibiting its activity in various biological pathways. Notably, these compounds can cross the blood-brain barrier, making them valuable for treating diseases that involve c-Abl, such as cancers, motor neuron diseases, and neurodegenerative disorders. The patents also detail methods for making and utilizing these c-Abl inhibitory compounds.

Career Highlights

Throughout her career, Silvana Zanlungo has worked with esteemed organizations, including the National Institutes of Health, a component of the US Department of Health & Human Services, and Pontificia Universidad Catolica De Chile. Her experience in these institutions has allowed her to advance her research and contribute to significant scientific discoveries.

Collaborations

Zanlungo has collaborated with notable colleagues, including Juan Jose Marugan and Marc Ferrer. These partnerships have enriched her research and expanded the impact of her innovations in the field.

Conclusion

Silvana Zanlungo's work in developing c-Abl tyrosine kinase inhibitors represents a significant advancement in therapeutic research. Her contributions are poised to make a meaningful impact on the treatment of various diseases.